Company News: Forest Labs, Almirall, Johnson & Johnson and Ethicon

Share this article:
Forest Labs entered a collaboration with Almirall to develop, market and distribute Almirall's LAS100977, a Phase II long-acting beta2 agonist, in the US. LAS100977 expands Forest's respiratory pipeline for COPD and marks the second such agreement between the firms. Three years ago, they teamed up on Eklira (aclidinium bromide), which is in Phase III for COPD.

Johnson & Johnson operating company Ethicon said it is acquiring Acclarent, a privately held maker of minimally-invasive devices used in sinus surgery, for $785 million in cash. In a statement, J&J said the acquisition of Acclarent gives Ethicon a new growth platform in ENT-related conditions. The transaction is expected to close in the first quarter of 2010.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Novartis apologizes for slow reporting

Novartis is apologizing to Japan after the Ministry of Health, Labor and Welfare said the company had dragged its feet reporting adverse events for two of its cancer drugs.

J&J pulls morcellator from market

The company is calling the move a withdrawal, as opposed to a recall.

Pfizer buys two Baxter vaccines

The meningitis and encephalitis medications earned a combined $300 million last year.